Cargando…

Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis

INTRODUCTION: Influenza is an important cause of morbidity and mortality in Europe. Prevention by annual vaccination is most effective but with yearly vaccine reformulation to match circulating virus strains, vaccine safety must be continuously monitored. The European Medicines Agency published guid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dos Santos, Gael, Shende, Vishvesh, Damaso, Silvia, Yeakey, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6860958/ https://www.ncbi.nlm.nih.gov/pubmed/31595482 http://dx.doi.org/10.1007/s12325-019-01105-2

Ejemplares similares

Brand-Specific Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season
por: Dos Santos, Gael, et al.
Publicado: (2019)

Passive enhanced safety surveillance of GSK’s quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season
por: Dos Santos, Gaël, et al.
Publicado: (2019)

Brand-specific enhanced safety surveillance of GSK’s Fluarix Tetra seasonal influenza vaccine in England: 2017/2018 season
por: de Lusignan, Simon, et al.
Publicado: (2020)

Safety Profile of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season
por: Salamanca de la Cueva, Ignacio, et al.
Publicado: (2021)

Brand-Specific Enhanced Safety Surveillance Study of GSK’s Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season
por: Dos Santos, Gaël, et al.
Publicado: (2021)

Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis
por: de Lusignan, Simon, et al.
Publicado: (2018)

Enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient‐reported outcome system for vaccine safety remote monitoring
por: Dos Santos, Gaël, et al.
Publicado: (2023)

Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19
por: Subissi, Lorenzo, et al.
Publicado: (2020)

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
por: Jagielska, Anna M., et al.
Publicado: (2021)

Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season
por: Serradell, Laurence, et al.
Publicado: (2020)

4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany
por: Eichner, Martin, et al.
Publicado: (2014)

Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine
por: Domnich, Alexander, et al.
Publicado: (2023)

The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study
por: Pospelov, Evgeny V., et al.
Publicado: (2020)

Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany
por: Molnar, Daniel, et al.
Publicado: (2022)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
por: Thorrington, Dominic, et al.
Publicado: (2017)

571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine
por: Singh, Tina, et al.
Publicado: (2022)

No safety signals for GSK quadrivalent influenza vaccine
Publicado: (2022)

On the Influence of the Seasons on the Mortality at Different Ages in Belgium
Publicado: (1839)

Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness — United States, February 2018
por: Flannery, Brendan, et al.
Publicado: (2018)

Interim Estimates of 2018–19 Seasonal Influenza Vaccine Effectiveness — United States, February 2019
por: Doyle, Joshua D., et al.
Publicado: (2019)

Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection
por: Kackos, Christina M., et al.
Publicado: (2023)

Enhanced passive safety surveillance of high‐dose and standard‐dose quadrivalent inactivated split‐virion influenza vaccines in Germany and Finland during the influenza season 2021/22
por: Gandhi‐Banga, Sonja, et al.
Publicado: (2022)

Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season
por: Ganczak, Maria, et al.
Publicado: (2019)

Excess hospitalizations and mortality associated with seasonal influenza in Spain, 2008–2018
por: Pumarola, T., et al.
Publicado: (2023)

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines
por: Habib, Md Ahsan, et al.
Publicado: (2023)

Correction to: 571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine
Publicado: (2023)

Seasonal Bordetella pertussis pattern in the period from 2008 to 2018 in Germany
por: Hitz, Daniel Allermann, et al.
Publicado: (2020)

Seasonal influenza surveillance: Observational study on the 2017–2018 season with predominant B influenza virus circulation
por: Basile, L., et al.
Publicado: (2019)

Seasonal influenza surveillance: Observational study on the 2017–2018 season with predominant B influenza virus circulation
por: Basile, L., et al.
Publicado: (2019)

Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
por: Amicizia, Daniela, et al.
Publicado: (2023)

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
por: Krishnarajah, Girishanthy, et al.
Publicado: (2021)

Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) — United States, 2018–19 Influenza Season
por: Grohskopf, Lisa A., et al.
Publicado: (2018)

A comparison of coronavirus disease 2019 and seasonal influenza surveillance in five European countries: France, Germany, Italy, Spain and the United Kingdom
por: Rigoine de Fougerolles, Thierry, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland
por: Nguyen, Van Hung, et al.
Publicado: (2023)

Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21
por: Syrkina, Olga, et al.
Publicado: (2022)

Effectiveness of the Cell-Derived Inactivated Quadrivalent Influenza Vaccine in Individuals at High Risk of Influenza Complications in the 2018–2019 United States Influenza Season
por: Boikos, Constantina, et al.
Publicado: (2021)

Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18
por: Castilla, Jesús, et al.
Publicado: (2018)

Forecasting next season’s Ixodes ricinus nymphal density: the example of southern Germany 2018
por: Brugger, Katharina, et al.
Publicado: (2018)

Genome-wide characterization and phylogenetic analysis of GSK gene family in three species of cotton: evidence for a role of some GSKs in fiber development and responses to stress
por: Wang, Lingling, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jvadeo862ipaj817hpcumkv3gi